Contact this trialFirst, we need to learn more about you.
Antioxidant
N-acetylcysteine for Retinitis Pigmentosa
Recruiting2 awardsPhase 1
Baltimore, Maryland
This trial is testing if N-acetylcysteine, an antioxidant, can help treat Retinitis Pigmentosa, a disease which causes progressive vision loss and eventual blindness. So far, the maximum tolerated dose of NAC has been 1800mg twice a day.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.